Peregrine Pharmaceuticals (PPHM) Earnings: An Early Look – Celgene Corporation (CELG)

Earnings season is winding down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Peregrine Pharmaceuticals (NASDAQ:PPHM) is about to release its quarterly earnings. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Peregrine Pharmaceuticals (NASDAQ:PPHM)Peregrine Pharmaceuticals (NASDAQ:PPHM) is one of many small biotech companies still looking to get their first drugs approved. Despite having very little in the way of revenue, the company has had a lot happening with it lately. Let’s take an early look at what’s been happening with Peregrine Pharmaceuticals (NASDAQ:PPHM) over the past quarter and what we’re likely to see in its quarterly report on Tuesday.

Stats on Peregrine Pharmaceuticals

Analyst EPS Estimate ($0.07)
Year-Ago EPS ($0.13)
Revenue Estimate $3.9 million
Change From Year-Ago Revenue 19%
Earnings Beats in Past 4 Quarters 3

Source: Yahoo! Finance.

What’s been happening with Peregrine Pharmaceuticals this quarter?
Analysts have raised their estimates slightly on Peregrine Pharmaceuticals (NASDAQ:PPHM) over the past few months, reducing their loss expectations by a penny per share for the just-ended quarter and by $0.03 per share for the full 2013 fiscal year. The stock has reflected even more optimism, rising nearly 30% since early December, but having given back much bigger gains from earlier this year.

Lately, investors have been on a roller-coaster ride with Peregrine Pharmaceuticals (NASDAQ:PPHM)’s stock. Last September, the company said that its own favorable clinical trial results for its most promising pipeline cancer drug, bavituximab, weren’t trustworthy, sending the shares down 80%. Yet by November, investors were getting more confident about the stock, seeing that mistakes made in the trial didn’t necessarily mean the drug didn’t work.

Then, in January, Peregrine said its third-party vendor had only mixed up part of its trial data, drawing favorable conclusions from the accurate part of the trial. Yet without explicit statistical analysis of the results, it’s hard for investors to compare bavituximab’s effectiveness against Celgene Corporation (NASDAQ:CELG)‘s rival pancreatic-cancer drug Abraxane.

In its earnings report, Peregrine Pharmaceuticals (NASDAQ:PPHM) needs to be as forthcoming about the bavituximab trial, providing as much statistical analysis as possible to help support its assertions that the drug has good prospects. Without that, it’s hard to see investors regaining confidence in the stock over the long haul.

The article Peregrine Pharmaceuticals Earnings: An Early Look originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 9 Most Dangerous Countries for Tourists to Visit

Reign of Terror: The 10 Most Ruthless Politicians in History

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!